ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1943

The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis

Victoria Saferding1, Melanie Hofmann 2, Julia S. Brunner 2, Mihaela F. Militaru 2, Antonia Puchner 2, Silvia Hayer 2, Melanie Timmen 3, Richard Stange 3, Josef Smolen 2 and Stephan Blüml 4, 1Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, 2Medical University of Vienna, Vienna, Austria, 3University Hospital Muenster, Muenster, Germany, 4Medical University of Vienna, Vienna

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: miRNA, osteoblast, osteoclast and osteoporosis, wnt5a

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Genetics, Genomics & Proteomics Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Micro RNAs (miRNAs) play a crucial role in the regulation of bone metabolism. MiR-146a, an important anti-inflammatory miRNA, was found to negatively impact osteogenesis and bone regeneration in vitro, by controlling the differentiation of mesenchymal stem cells. But to date the role of miR-146a in bone remodelling, its influence on bone stability and development of osteoporosis is not known.

Methods: Systemic bone, tibiae and femur, of wt, miR-146a-/- and miR- 146a-/- TRAF6+/- animals was assessed histologically and via µCT analysis, over a period of 3 to 18 months of age. Serum cytokine levels were analysed by Elisa. MRNA expression levels in bone were analysed by qPCR. To induce osteoporosis, ovariectomy (OVX) induced bone loss was performed.

Results: When we analysed bone volume of long bones histologically as well as with µCT analysis we detected significantly increased trabecular as well as cortical bone mass in miR-146a deficient compared to wt animals, starting at an age of 6 months. Dose reduction of TRAF6, a main target of miR-146a, using miR-146a-/- TRAF6+/- animals could not change the observed bone phenotype. Analysis of serum in aged miR-146a deficient animals displayed elevated activity of bone resorbing osteoclasts as amounts of CTX I in miR-146a-/- mice were significantly increased compared to wt animals. Q-PCR analysis of important osteoclast as well as osteoblast marker genes in bones ex vivo displayed elevated expression of signature molecules of both cell types in aged miR-146a deficient mice, suggesting a regulatory role of miR-146a in both cell types. Moreover, expression level of Wnt5a, a known target of miR-146a, influencing bone forming as well as bone resorbing cells, was strongly elevated in miR-146a-/- bones, possibly responsible for this deregulated bone growth. When we induced osteoporosis using the OVX disease model, histological analysis of long bones showed significant trabecular bone loss in ovariectomized wt mice. In contrast, we could not detect trabecular bone loss in ovariectomized miR-146a knock out animals, suggesting that loss of miR-146a deficiency protects bone loss induced by estrogen deficiency.

Conclusion: MiR-146a seems to control bone turnover and miR-146a deficient mice accrue bone over time. Moreover this miRNA has a negative influence on bone loss occurring during oestrogen loss induced osteoporosis. Therefore, miR-146a could be possibly used as a therapeutic target in the treatment of osteoporosis. 


Disclosure: V. Saferding, None; M. Hofmann, None; J. Brunner, None; M. Militaru, None; A. Puchner, None; S. Hayer, None; M. Timmen, None; R. Stange, None; J. Smolen, AbbVie, Amgen, Astra-Zeneca, Astro, Celgene Corporation, Celtrion, Eli Lilly, Glaxo, 8, AbbVie, Eli Lilly, Janssen, MSD, Pfizer, Roche, 2, ILTOO, Janssen, Medimmune, MSD, Novartis, Pfizer, Roche, Samsung, Sanofi, UCB, 8; S. Blüml, None.

To cite this abstract in AMA style:

Saferding V, Hofmann M, Brunner J, Militaru M, Puchner A, Hayer S, Timmen M, Stange R, Smolen J, Blüml S. The Emerging Regulatory Function of microRNA146a in Bone Biology and Osteoporosis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/the-emerging-regulatory-function-of-microrna146a-in-bone-biology-and-osteoporosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-emerging-regulatory-function-of-microrna146a-in-bone-biology-and-osteoporosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology